Metformin Activity against Breast Cancer: Mechanistic Differences by Molecular Subtype and Metabolic Conditions
Obesity and type 2 diabetes increase the risk of and reduce survival in breast cancer (BC) patients. Metformin is the only anti-diabetic drug that alters this risk, with a reduction in BC incidence and improved outcomes. Metformin has AMP-kinase (AMPK) dependent and independent mechanisms of action,...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2020
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/71075 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Metformin Activity against Breast Cancer: Mechanistic Differences by Molecular Subtype and Metabolic Conditions
- Metformin and Pancreatic Cancer Metabolism
- Correlation between Ultrasound Findings and Molecular Subtypes of Breast Cancer
- Integrating Protein Sequence and Expression Level to Analysis Molecular Characterization of Breast Cancer Subtypes
- Label-Space Mismatch Distorts Cross-Cohort Evaluation in Breast Cancer Molecular Subtyping
- Subtypes of Thyroid Cancer and Their Molecular Pathogenesis
- Breast Cancer Molecular Subtypes Prediction on Pathological Images with Discriminative Patch Selecting and Multi-Instance Learning